UPDATED May 04, 2024
Potentially undervalued companies with a strong past performance and robust balance sheet.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
EKTA B | kr76.95 | 1.8% | -12.6% | kr29.4b | kr83.42 | PE20.5x | E14.5% | 3.1% | ||
ARJO B | kr45.88 | -1.2% | -1.5% | kr12.5b | kr51.25 | PE25x | E21.1% | 2.0% | ||
SUS | kr154.10 | 3.6% | -18.5% | kr7.9b | kr221.50 | PE33.6x | E22.0% | n/a | ||
CEVI | kr226.50 | 2.7% | 22.0% | kr5.4b | kr257.50 | PE38.3x | E23.6% | 1.0% | ||
RAY B | kr118.40 | 1.2% | 59.1% | kr4.1b | kr135.00 | PE49.8x | E34.7% | 0.6% | ||
CRAD B | kr37.80 | -2.3% | 16.0% | kr1.3b | kr58.00 | PE35.8x | E34.9% | n/a | ||
CARE | kr29.00 | 7.4% | 81.3% | kr705.5m | kr28.50 | PE15.4x | E16.8% | n/a | ||
DEDI | kr56.90 | -6.0% | -55.1% | kr544.1m | kr120.00 | PE5.6x | E6.1% | 11.4% | ||
BOUL | kr10.00 | 2.0% | -17.2% | kr388.3m | kr10.40 | PE15.5x | E23.9% | 0% | ||
ARCOMA | kr13.10 | -3.0% | 59.8% | kr172.7m | kr15.00 | PE18.4x | E20.5% | n/a |